Partners

The UltiMalVax consortium has an incredibly wide expertise and experience with immunogen design, pre-clinical immunogenicity and efficacy models of malaria, immunoassays of functional antibodies and other potential immune correlates.

​

Novel technologies from biotech companies prepared to provide access to these for malaria (e.g. thermostable mRNA), a leading PDP with a long malaria vaccine track record as coordinator, access to a leading licensed saponin adjuvant and many promising new adjuvant formulations, GMP manufacturing capability, and deep expertise in vaccine clinical development and product licensure.